ALD vs MASLD Animal Models: Preclinical Comparison
ALD and MASLD share a similar disease spectrum but need distinct animal models. Compare Lieber-DeCarli, NIAAA, and MASH models for your fibrosis research.
Introduction: Two Similar Yet Distinct Steatotic Liver Diseases
"Fatty liver" describes the excessive accumulation of triglycerides in the liver. Its causes are broadly divided into two major categories: One is ALD (Alcohol-associated Liver Disease), driven by excessive alcohol consumption. The other is MASLD (Metabolic dysfunction-Associated Steatotic Liver Disease), based on metabolic abnormalities such as obesity and diabetes.
Clinically, both share a common disease spectrum: progressing from "Simple Steatosis" to "Steatohepatitis", "Fibrosis/Cirrhosis", and eventually "Hepatocellular Carcinoma (HCC)".
However, from the perspective of preclinical drug discovery—specifically, "how to reproduce this in animal models (mice/rats)"—the approaches are completely different. In this article, we explain the decisive differences between ALD and MASLD animal models and how to select the appropriate model for your research objectives.
1. Fundamental Differences in Pathogenesis
To understand the models, we must first understand the differences in the "initial trigger" of the pathology.
MASLD / MASH (Non-Alcoholic)
- Primary Triggers: Calorie surplus (high fat, high fructose, high cholesterol), insulin resistance, obesity.
- Core Toxicity: Lipotoxicity from excess free fatty acid (FFA) influx, oxidative stress, and microbiome alterations.
- Progression: Metabolic abnormalities gradually activate liver Kupffer cells (macrophages) and stellate cells, causing chronic inflammation and progressive fibrosis.
ALD (Alcohol-Associated)
- Primary Triggers: Ethanol (alcohol) and its metabolites.
- Core Toxicity: Acetaldehyde (highly toxic) generated during ethanol metabolism, and a sudden burst of Reactive Oxygen Species (ROS) induced by the CYP2E1 enzyme.
- Progression: Direct hepatocyte damage by acetaldehyde, coupled with endotoxin (LPS) influx into the liver due to alcohol-induced destruction of the intestinal barrier (leaky gut), triggers intense acute and chronic inflammation.
For researchers tracking fibrosis & inflammation R&D
FDA approval alerts, trial readouts, preclinical model selection, and assay optimization — curated signal for bench-to-pipeline readers. 2 emails/month max.
2. Representative MASLD / MASH Models (A Review)
The goal of MASLD models is to balance systemic "obesity/metabolic dysfunction" with "fibrosis". The use of older models like the AMLN diet has rapidly declined because their reliance on high industrial trans-fats—which the FDA has increasingly restricted in human food—creates a metabolic profile that diverges from modern clinical pathology.
- GAN Diet Model: Feeding a diet high in fat, fructose, and cholesterol over time (12-24 weeks) to naturally reproduce systemic metabolic abnormalities (obesity, insulin resistance) alongside progressive fibrosis. Currently the gold standard for clinical translatability.
- CDAHFD (Choline-Deficient, L-Amino Acid-Defined, High-Fat Diet) Model: Forces rapid steatosis and fibrosis by fundamentally blocking the liver's ability to export lipids (via VLDL). Importantly, this model lacks systemic metabolic syndrome features—animals often lose weight and lack severe insulin resistance. It functions more effectively as a rapid "fibrosis-promoter" rather than a true physiological MASH model.
- STAM Model: Administering streptozotocin (STZ) in the neonatal period to create a diabetic predisposition, followed by a high-fat diet. This model rapidly progresses from MASH to HCC.
Read our detailed guide on evaluating and selecting MASH models here
3. Representative ALD (Alcohol-Associated) Models
The biggest challenge with alcohol models is that "mice do not voluntarily drink large amounts of alcohol" and "their alcohol metabolism is much faster than humans." Simply mixing alcohol into their drinking water rarely induces severe hepatitis or fibrosis.
Therefore, specialized models forcing alcohol consumption as a caloric source were developed.
① Lieber-DeCarli Liquid Diet Model (Chronic Alcohol Consumption)
Developed in the 1960s, this is the classic and foundational model of ALD research.
- Method: Solid food is removed, and mice are fed exclusively a "Liquid Diet" mixed with ethanol. Alcohol accounts for ~35-36% of total caloric intake.
- Pros: Maintains stable blood alcohol concentrations similar to human heavy drinkers over several weeks.
- Cons: While it reproduces steatosis and mild inflammation, it does not lead to obvious fibrosis. It is notoriously difficult for mice to develop cirrhosis from alcohol alone.
② NIAAA Model (Gao-Binge / Chronic-Binge Model)
Currently the most widely used breakthrough model for ALD mechanism analysis and anti-inflammatory drug screening.
- Method: Mice are fed the Lieber-DeCarli liquid diet (5% ethanol) for 10 days to several weeks to create chronic alcoholic steatosis, followed by a single large intragastric "Binge" dose of ethanol at the end.
- Mechanism: Faithfully reproduces the human onset pattern of Acute Alcoholic Hepatitis: "A chronic heavy drinker who engages in an episode of severe binge drinking."
- Pros: Rapidly reproduces sharp spikes in ALT/AST, dramatic neutrophil infiltration, and intense oxidative stress.
- Cons: While excellent as an acute injury/inflammation model, it still takes considerable time to reproduce advanced "fibrosis" using this method alone.
③ ALD Fibrosis Models (Combination Models)
Because fibrosis is hard to achieve with alcohol alone, hybrid models combining alcohol with "other fibrotic triggers" are utilized.
- Alcohol + Carbon Tetrachloride (CCl4): Repeated low-dose administration of CCl4 (a powerful hepatotoxin) under chronic alcohol consumption. Because alcohol induces CYP2E1 (the enzyme that metabolizes CCl4), the powerful synergistic effect rapidly forms severe fibrosis in just 4-8 weeks.
- Western Diet + Alcohol: A hybrid feeding model simulating "MetALD"—combining a fatty liver-promoting diet (high fat) with alcohol consumption.
4. Model Selection Checklist
The model you choose must align perfectly with your drug's target—whether that targets MASLD or ALD pathways.
| Target Evaluated | Optimal Animal Model |
|---|---|
| MASH with Systemic Obesity / Insulin Resistance | GAN Diet Model |
| Rapid Fibrosis Evaluation (Regardless of Obesity/Metabolism) | CDAHFD Diet Model |
| Alcohol Toxicity / Acute Alcoholic Inflammation | NIAAA Model (Chronic-Binge Model) |
| Fibrosis Inhibition in Alcohol Dependencies | Alcohol + CCl4 Combination Model |
| Metabolic Syndrome + Alcohol (MetALD) | Western Diet Liquid Base + Alcohol Model |
Conclusion: Translation to Clinical Pathology
Although the initial "steatosis" phase looks similar, ALD and MASLD differ significantly in the underlying inflammatory signals (e.g., acetaldehyde oxidative stress vs. lipotoxicity) and the dominant immune cell balance (neutrophil-dominant vs. macrophage-dominant).
In preclinical studies, carelessly assuming "both are fatty liver" and repurposing the wrong model will likely lead to massive targeting failures (the "Valley of Death") when moving to clinical trials. The shortcut to success is determining whether your compound's Mechanism of Action (MoA) addresses the alcohol-derived damage cascade or the metabolism-derived cascade, and selecting the appropriate model accordingly.